Navigation Links
EXAMINE-Studie zur kardiovaskulären Sicherheit von Alogliptin erreicht primären Endpunkt: keine Erhöhung des kardiovaskulären Risikos bei Risikopatienten mit Typ-2 Diabetes
Date:9/11/2013

12,5 mg bzw. 25 mg zugelassen. Bei Patienten mit einer moderaten Einschränkung der Nierenfunktion (Creatinin-Clearance [CrCl] > 30 bis < 50 ml/min) beträgt die Dosis Alogliptin einmalig 12,5 mg pro Tag, und bei Patienten mit schwerer Einschränkung der Nierenfunktion (CrCl > 15 bis < 30 ml/min) und solchen mit Nierenerkrankungen im Endstadium (ESRD) (CrCl < 15 ml/min oder mit Hämodialysebedarf) beträgt die Dosis Alogliptin einmalig 6,25 mg pro Tag.

Alogliptin ist in Europa derzeit noch nicht zugelassen. VIPIDIA (Alogliptin), VIPDOMET (Alogliptin und Metformin FDC) sowie INCRESYNC (Alogliptin und Pioglitazon FDC) werden gegenwärtig von der Europäischen Arzneimittel-Agentur (EMA) geprüft und wurden vom Committee for Medicinal Products for Human Use (CHMP) im Juli 2013 positiv bewertet. Alogliptin wurde auch zur Anwendung in China, Mexiko und Südkorea zugelassen, obgleich die Therapie auf diesen Märkten noch nicht erhältlich ist.

Die Wirksamkeit von Alogliptin wurde als Ergänzung zu Diät und Bewegung sowie als Zusatztherapie für andere Antidiabetika untersucht, darunter Metformin, Pioglitazon, Insulin und Sulfonylharnstoffe. In diesen Studien wurde Alogliptin als 25-mg-Tablette einmal täglich eingenommen und zeigte eine klinisch und statistisch signifikante Reduzierung des HbA1c mit einem guten Verträglichkeitsprofil und einer geringen Hypoglykämie-Rate im Vergleich zur aktiven Kontrolle oder Placebo. Studienergebnisse legten nahe, dass Alogliptin bei gemeinsamer Verabreichung mit Metformin oder Pioglitazon in einer jeweiligen Therapie mit freier Dosierung zu einer wesentlichen Verbesserung der Blutzuckerkontrolle führte.

Informationen zu Takeda Pharmaceutical Company Limited
Takeda ist in Osaka, Japan, ansässig und ist ein weltweit agierendes Unternehmen mit Schwerpunkt
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. American College of Chest Physicians (ACCP) und Simbionix arbeiten zusammen, um klinische Ausbildung und Patientensicherheit zu verbessern
2. Messe/Konferenz InnoPack Pharma legt den Fokus auf innovative Verpackungen für Compliance und Sicherheit
3. Takeda EXAMINE Cardiovascular Safety Outcomes Trial of Alogliptin Met Primary Endpoint of Non-Inferiority Compared to Placebo in Addition to Standard of Care Showing No Increase in Cardiovascular Risk in Type 2 Diabetes Patients at High-Risk for Car
4. Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States
5. Takeda Receives FDA Approval for Three New Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl)
6. Takeda Resubmits New Drug Applications to the United States Food and Drug Administration for Alogliptin and the Fixed-Dose Combination Alogliptin and Pioglitazone
7. National Diabetes Volunteer Leadership Council (NDVLC) Urges FDA to Enforce Stringent Accuracy Standards for Blood Glucose Monitoring Systems
8. Clinilabs Sponsors The ADAs 2013 Step Out: Walk to Stop Diabetes
9. GSMA mHealth Grand Tour Highlights How Mobile Technology Could Help Prevent 5 Million People In The EU From Developing Diabetes
10. Elcelyx Therapeutics NewMet for Type 2 Diabetes Meets Primary Endpoint in Phase 2b Study
11. Bio-Solutions Corp. Expanding in Booming Diabetes Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 2014 InformEx, North America,s leading ... will hold the 30 th edition of its annual ... Center from January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... fine chemical and specialty chemical companies will take part in ...
(Date:1/14/2014)... , Jan. 14, 2014 Animal Emergency Critical Care, a LifeCentre ... Leesburg, Virginia is the first in Loudoun ... Dr. Susan M. Barnes , Medical Director, ... and husband, Dr. Cole Taylor , are avid scuba divers. ...
(Date:1/14/2014)... January 14, 2014 Equashield ( ... hazardous drugs, today announced that it has achieved ... year.   Equashield,s closed systems reduce ... nurses and other medical professionals who prepare and ...
Breaking Medicine Technology:Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2Equashield's Sales Grow by 60% in 2013 2
(Date:4/23/2014)... could help doctors predict which patients might suffer potentially ... The program, which assesses brain scans using pattern recognition ... passport control, has been developed by researchers at Imperial ... the Wellcome Trust, which used the software are published ... Stroke affects over 15 million people each year worldwide. ...
(Date:4/23/2014)... 2014) The American Gastroenterological Association (AGA) Research ... Research Scholars. The AGA Research Scholar Awards program, ... independent and productive research careers in digestive diseases. ... an additional year allowing for three consecutive years ... junior faculty who are paving the way for ...
(Date:4/23/2014)... vegetables are often displayed in the popular Swedish ... plenty of high-sugar foods. A new study from ... portrayed in children,s TV programmes as well as ... habits and weight status. , Steingerdur Olafsdottir,s doctoral ... the popular Swedish children,s TV show Bolibompa. Healthy ...
(Date:4/23/2014)... Five for-profit and non-profit organizations in Washington ... Proof of Concept grants to accelerate maturation of ... the Life Sciences Discovery Fund (LSDF) announced today. ... grant to the Washington Biotechnology & Biomedical Association ... train the next generation of entrepreneurs and help ...
(Date:4/23/2014)... physicians concerned about an increase in adolescents, marijuana use ... sigh of relief. According to a new study at ... data from states with and without medical marijuana laws, ... among adolescents. The study is published online in advance ... . , "Any time a state considers legalizing ...
Breaking Medicine News(10 mins):Health News:Airport security-style technology could help doctors decide on stroke treatment 2Health News:Airport security-style technology could help doctors decide on stroke treatment 3Health News:AGA announces 2014 Class of AGA Research Scholars 2Health News:High-calorie and low-nutrient foods in kids' TV 2Health News:LSDF announces commercialization grants and Entrepreneur Mentoring Program 2Health News:RI Hospital physician: Legalizing medical marijuana doesn't increase use among adolescents 2
... , , , MORRISTOWN, ... WPI ), a leader in generic and specialty branded ... Company as Executive Vice President, Global Brands. In this ... aspects of the Company,s global brand pharmaceutical business, including brand ...
... BALTIMORE, Sept. 21 A new survey from ... is contributing to acute, or short-term, physical pain for Americans. ... Month, 68 percent of people who experienced acute back pain ... year said that the recession caused, increased or affected their ...
... , , BIRMINGHAM, Ala., Sept. 21 ... that it has received a request for proposal (RFP) from the ... of intravenous (i.v) peramivir for the treatment of critically ill influenza ... The RFP indicates that the minimum and maximum order ...
... , , INDIANAPOLIS, Sept. 21 ... nonsquamous patients with advanced non-small cell lung cancer (NSCLC) who received ... as compared to placebo plus best supportive care. , ... studies looking at the use of histology to tailor treatment with ...
... DETROIT, Sept. 21 Webahn, Inc. announces the launch of ... Electronic Medical Records service Capzule.com and Accent, a voice recording ... , Capzule enables physicians to access patient information ... capability to send messages, add notes, prescribe medications and write ...
... is a serious condition that involves the formation of a ... legs. A patient with DVT is typically treated with anticoagulants ... procedures may play a more central role in the long-term ... October issue of the American Journal of Roentgenology ...
Cached Medicine News:Health News:Watson Names G. Frederick Wilkinson Executive Vice President, Global Brands 2Health News:Watson Names G. Frederick Wilkinson Executive Vice President, Global Brands 3Health News:Economic Pain Contributing to Acute Physical Pain for Many Americans, New Survey Says 2Health News:Economic Pain Contributing to Acute Physical Pain for Many Americans, New Survey Says 3Health News:Economic Pain Contributing to Acute Physical Pain for Many Americans, New Survey Says 4Health News:BioCryst Receives Peramivir Request for Proposal From the U.S. Government 2Health News:BioCryst Receives Peramivir Request for Proposal From the U.S. Government 3Health News:BioCryst Receives Peramivir Request for Proposal From the U.S. Government 4Health News:Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 2Health News:Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 3Health News:Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 4Health News:Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 5Health News:Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 6Health News:Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 7Health News:Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 8Health News:Voice, Medical Records iPhone Apps Launched for Physicians 2Health News:Image-guided treatment for deep venous thrombosis could improve patients' long-term outcomes 2
... Available in small and large sizes, ... popular, easy-to-place, silver/silver chloride disposable tabs. For ... 17). Dimensions (contact surface): large tabs-2.2 x ... tabs-1.5 cm (0.5 in) square. Each 100-count ...
... Symphony orchestrates images and patient information ... information sources in one central system. ... and improves cost-effectiveness so that healthcare ... do best, helping people., ,Many Sources, ...
... Maxenon Xi300 is so bright many surgeons turn ... gears to shift into when the going gets ... as a true Hot Start and the technologically ... system that prevent failed start ups and overheating. ...
Mounted on a sturdy, molded headband,the Classic has a fully adjustable crown,strap and cushioning that adds to,your comfort....
Medicine Products: